Welcome to our dedicated page for AtriCure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on AtriCure stock.
AtriCure, Inc. (symbol: ATRC) is a leading provider of cutting-edge medical technologies aimed at treating atrial fibrillation (Afib) and related conditions. With over 33 million people affected by Afib globally, AtriCure stands at the forefront of developing innovative solutions to combat this prevalent health issue. Electrophysiologists and cardiothoracic surgeons around the world rely on AtriCure's products to reduce complications associated with Afib.
The company's flagship product, the Isolator® Synergy™ Ablation System, is notably the first and only device approved by the FDA for the treatment of persistent Afib. Additionally, the AtriClip Left Atrial Appendage Exclusion System holds the title of the most widely sold LAA management device globally, with over 100,000 units implanted to date.
AtriCure's diverse product line includes solutions for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, among others. They also offer a range of minimally invasive ablation devices and access tools catering to the increasing demand for less invasive cardiac and thoracic surgeries. Their products are distributed to medical centers through a combination of a direct sales force and a network of distributors.
Geographically, the majority of AtriCure's revenue is generated from the United States. The company continues to expand its impact through ongoing projects, research, and partnerships aimed at improving patient outcomes and advancing the field of cardiac surgery.
For more detailed information about AtriCure's latest developments, visit their official website at AtriCure.com or follow them on Twitter @AtriCure.
AtriCure, Inc. (NASDAQ: ATRC), known for its innovative therapies for atrial fibrillation (Afib) and related conditions, announced an upcoming investor education webcast in collaboration with Canaccord Genuity, focusing on Cryo Nerve Block Therapy. This event is scheduled for May 16, 2023, at 12:30 PM Eastern Time, featuring a Q&A session with management and a key opinion leader.
Additionally, AtriCure will present at the 2023 Bank of America Health Care Conference on May 10, 2023, at 11:00 AM Eastern Time. Both events aim to enhance investor understanding of AtriCure's cutting-edge technologies, including the Isolator® Synergy™ Ablation System, which is FDA-approved for persistent Afib treatment.
Interested participants can access live and archived webcasts through the Investors section of AtriCure's website.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its first quarter 2023 financial results will be released on May 2, 2023. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested participants can register here. AtriCure focuses on innovative technologies for Afib treatment, with products like the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, addressing a condition affecting over 37 million people worldwide.
AtriCure, a leader in innovative surgical treatments for atrial fibrillation (Afib), announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The company’s management will conduct a fireside chat on April 17, 2023, at 1:30 PM EST. Interested parties can access a live audio webcast in the ‘Investors’ section on AtriCure's website. AtriCure focuses on the development of technologies for Afib treatment and LAA management, with over 37 million individuals affected by Afib globally. The firm’s devices, including the Isolator® Synergy™ Ablation System and the AtriClip® LAA Exclusion System, are widely used by healthcare professionals.
AtriCure, Inc. (Nasdaq: ATRC) reported a 20.4% increase in worldwide revenue for 2022, totaling $330.4 million. U.S. revenue reached $277.2 million, up 21.0%, while international sales rose 17.7% to $53.2 million. The fourth quarter revenue was $88.0 million, marking a 20.2% increase year-over-year. Despite strong growth, the company reported a loss from operations of $42.7 million for 2022, alongside a net loss per share of $1.02. Looking ahead, 2023 revenue is projected between $380 million and $387 million, reflecting growth of 15% to 17%. The company aims for adjusted EBITDA to break even in 2023.
AtriCure, Inc. (NASDAQ: ATRC) announced its participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 15, 2023, at 8:00 am EST. The conference will feature a presentation by AtriCure's management team. Interested investors can access the live audio webcast through the 'Investors' section of AtriCure’s website. AtriCure is known for its innovative surgical treatments targeting atrial fibrillation (Afib) and related conditions. The company provides several unique products, including the Isolator® Synergy™ Ablation System and AtriClip® LAA management devices.
AtriCure, Inc. has initiated the LeAAPS clinical trial to assess the safety and effectiveness of its AtriClip® LAA Exclusion System for stroke prevention in cardiac surgery patients. The trial, involving up to 6,500 patients across 250 centers worldwide, is notable for being the largest randomized trial in surgical LAA exclusion. The goal is to establish new treatment protocols for patients at risk of ischemic stroke. The AtriClip System is recognized as a leading device in LAA management. CEO Michael Carrel emphasized the trial's potential to enhance patient outcomes and expand market opportunities.
AtriCure, Inc. (NASDAQ: ATRC) announced its fourth quarter and full year 2022 financial results will be released on February 21, 2023. An audio webcast and investor meetings are scheduled for the same date and also on February 14, 2023, at the BTIG MedTech Conference in Snowbird, Utah. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, with FDA-approved technologies such as the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System. These advancements cater to over 37 million Afib patients globally, cementing AtriCure's position in the medtech industry.
FAQ
What is the current stock price of AtriCure (ATRC)?
What is the market cap of AtriCure (ATRC)?
What does AtriCure, Inc. specialize in?
What is the Isolator® Synergy™ Ablation System?
What is AtriClip?
How does AtriCure distribute its products?
What types of products does AtriCure offer?
Where does AtriCure generate most of its revenue?
Are AtriCure’s products used internationally?
What makes AtriCure's products unique?
Where can I find more information about AtriCure?
What are AtriCure’s latest achievements?
